Results 211 to 220 of about 667,209 (277)

PARP enzyme synthesis of protein-free poly(ADP-ribose): Implications for DNA damage signaling and repair. [PDF]

DNA Repair (Amst)
Langelier MF, Pascal JM.
europepmc   +1 more source

Effects of a cancer-associated mutation and multiple serine phosphorylation on poly(ADP-ribose) polymerase 2. [PDF]

Biophys J
Hughes B, Chatterjee S, Ghafari M, Cisneros GA.   +3 more
europepmc   +1 more source

Poly-ADP-ribosylation modulated by poly(ADP-ribose) polymerase 1 is associated with glucose metabolism in colorectal cancer cells. [PDF]

Transl Oncol
Zhang C, Wang P, Yu J, Yuan J, Zhang L, Li M.   +5 more
europepmc   +1 more source

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]

Molecules
Morgan I, Rennert R, Berger R, Hassanin A, Davari MD, Eisenschmidt-Bönn D, Wessjohann LA.   +6 more
europepmc   +1 more source

Correction: Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor.

Elife
Liu Q, Xiao Q, Sun Z, Wang B, Wang L, Wang N, Wang K, Song C, Yang Q.   +8 more
europepmc   +1 more source

Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases. [PDF]

DNA Repair (Amst)
Call N, Tomkinson AE.
europepmc   +1 more source

Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer. [PDF]

Cell Mol Life Sci
Maluchenko N, Saulina A, Geraskina O, Kotova E, Korovina A, Armeev G, Kirpichnikov M, Feofanov A, Studitsky V.   +8 more
europepmc   +1 more source

Poly (ADP-ribose) polymerase inhibitors in cancer therapy. [PDF]

Chin Med J (Engl)
Zhu Z, Shi Y.
europepmc   +1 more source

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]

Front Oncol
Uekusa R, Yokoi A, Watanabe E, Inoue M, Mizuno K, Yoshida K, Yoshikawa N, Niimi K, Suzuki S, Kajiyama H.   +9 more
europepmc   +1 more source

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]

BMC Cancer
Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y.   +17 more
europepmc   +1 more source